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Background
Treatment resistant depression is a loosely defined term typically used to describe
depressive episodes that have not responded sufficiently to trials of antidepressant
monotherapy (1, 3). The term “difficult to treat” has also been used to refer to
patients with depression who do not respond satisfactorily to antidepressants (4, 8).
In these patients, response to next-step treatments may be reduced (10 – 12), and
remission rates may be affected by comorbid anxiety disorders (14 – 16).
A depressive episode is qualified as severe when eight or nine symptoms that
define major depression are present (19). It is also generally characterized by
suicidal ideation and behavior, obvious impairment of functioning, and psychotic or
catatonic features (18).
Major depression was found to be less common in the elderly population (> 65) with
prevalence around half of that of adults aged 18 – 64 years (37, 38). When present,
it is also generally less severe and tends to occur in the elderly with a greater
burden of medical illness (37, 39). Rapid onset of depressive symptoms is less
likely to occur in patients with new onset depression (43).

Introduction
Here, we present a case of late life, rapid onset, severe, treatment resistant major
depression with psychotic features. This case with was considered for ECT but
ultimately responded to an unusual choice of pharmacotherapy. We highlight our
experience dealing with this uncommon presentation of a common disorder. We
discuss limitations to treatment and further recommendations when faced with difficult
to treat depression.

SECOND ADMISSION: *Because patient was in the community for less than 12 hours after her first discharge,
we will consider her readmission to be Hospital Day 13.* On Day 15, mirtazapine was increased to 45
mg QAM, and risperidone 0.5 mg QHS was added to address delusions of guilt (e.g. the
fear that returning home would precipitate her husband’s death).
Patient remained with the following symptoms: episodic poor PO intake, asthenia to the
point of gait instability, negativism, extreme pessimism, blunted affect, self-isolation, labile
crying spells, ruminations, perseverations, rocking behavior, self-injurious urges,
indecisiveness and cognitive retardation to the point medical decision-making capacity
was impaired at times, severe hopelessness (i.e. believing her functionality would never
improve). She also remained with some circadian rhythm dysfunction and refused three
doses of morning mirtazapine. Melatonin 3 mg QHS was added on Day 17.
Due to unusual presentation, patient was evaluated for OCD. Y-BOCS score was 7/40, and
patient denied history of compulsive or ritualistic behavior. On Day 20, hydroxyzine was
increased to 25 mg Q6h PRN to address continued anxious distress; patient used this
medication three to six times per week during hospitalization.
On Day 25, patient had her last dose of mirtazapine after receiving a total of 7 doses at 45
mg daily (18 doses total). She was switched to paroxetine 20 mg QAM on Day 26, while
risperidone and PRN hydroxyzine were continued. Paroxetine was increased to 30 mg QHS
on Day 33.
The possibility of ECT was discussed with patient and family. However, while patient and
family were still considering ECT, patient started to show some improvement, including:
reduced dysphoria and anxiety; increased appetite, energy, socialization, and interaction with
the treatment team.

Discussion

80 year old female with no psychiatric history or significant medical comorbidities was
admitted to LGBHU following an aborted suicide attempt. The patient had prepared a bottle of
her husband’s alprazolam prescription for overdose with lethal intent when she called her
daughter instead. Recent psychosocial stressors included husband’s medical illness with his
subsequent admission to a rehab unit.

Our elderly patient had a unique presentation to a common disorder; namely, she had a later
but rapid initial onset of illness. She was severely depressed, delusional, and anxious with
asthenia, affective lability, and rocking behaviors at various stages of her illness.

Initial labs: hypokalemia (3.2), hypoalbuminemia (3.2), hemoconcentration (Hb 16.7 / Hct
49.2), hyperglycemia (HbA1c 6.0), BUN 22, TSH 3.65; CBC & CMP were otherwise WNL
Patient had poor PO intake and was help-rejecting, initially declining all psychotropics. She
eventually consented to a trial of pharmacotherapy on Day 5 of hospitalization, conditional
upon a hypnotic effect. She was started on mirtazapine 15 mg QHS and hydroxyzine 10 mg
Q6h PRN anxiety. Mirtazapine was further increased to 30 mg QHS on Day 10. Patient had
modest symptom improvement, and she was discharged home on Day 12 with plan for close
supervision by her children, as husband remained at rehab.
WITHIN 12 HOURS OF DISCHARGE:
Discharge plan of constant home supervision was interrupted for approximately 3 hours.
Patient was overcome with anxiety due to home systolic BP reading in the 180’s. She called
EMS, but BP was normotensive; however, she requested readmission to inpatient psychiatry,
reportedly stating, "If I had a gun, I'd blow my head off.”

Difficulties in treating severely depressed patients on an inpatient setting include
limitations of the following: time to assess response to both antidepressants and
psychotherapy, access to specialized psychotherapy, access to other treatment
modalities (e.g. ECT), and loss to follow-up care. Oftentimes in the inpatient setting,
providers are faced with external pressure to quickly stabilize and discharge
patients. Despite this dilemma, providers should avoid premature adjustment of
medications or addition of other treatment modalities, as potential harm to the
patient could be introduced by overtreatment.
Moreover, treatment should be tailored to the patient’s specific needs and
preferences. Considerations for treatment should be based on specific depressive
symptoms, comorbid illnesses, prior medication trials, concurrent medications,
.
potential drug interactions, side effect profile, safety, ease of use, patient preference,
cost, and family history of medication response.
Some severely depressed elderly patients may benefit from paroxetine, despite the
risk of anticholinergic side effects, especially those with marked anxious distress or
obsessive-compulsive features.

On Day 40, after 7 doses of paroxetine 30 mg QHS (14 doses total) and 25 doses of
risperidone 0.5 mg QHS, the patient’s mood was “pretty good” and delusional thinking had
abated. ECT was ultimately not utilized, and patient was discharged home on Day 41 with
plan for increased structure and supervision by family supports. Notably, her husband had
also returned home by the date of discharge.

Hospital Course

Initial encounter: + dysphoria, SI, anhedonia, guilty ruminations, anergy, avolition, insomnia,
and anorexia with 15 - 20 lb. unintentional weight loss over 3 months.

Conclusion & Recommendations

Electroconvulsive therapy (ECT) was considered after nonresponse to antidepressants and
marked deterioration in functioning. ECT may be regarded as superior to pharmacotherapy
in patients with severe, treatment resistant major depression; with persistent suicidal ideation
with intent; or with severe weight loss secondary to hyporexia (21 - 33). In geriatric patients,
ECT may have a smaller risk of complications and potentially better treatment response
when compared to pharmacotherapy (34, 35).
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However, our patient’s indecisiveness and fluctuating decision-making capacity caused a
delay in preparations for ECT. In the meantime, she began to exhibit adequate response to
paroxetine treatment with risperidone augmentation. After failing a trial of mirtazapine,
paroxetine was chosen despite the patient’s age in an effort to better address her anxious
distress, obsessive-compulsive tendencies, and sleep disturbance.
According to the Beers Criteria and the Pharmacy Quality Alliance, paroxetine is identified as
a high-risk medication to be avoided in those 65 years and older due to its strong
anticholinergic properties, high potential for sedation, risk of hyponatremia, and risk of
orthostatic hypotension (41). In contrast, this case demonstrates that some elderly patients
may derive excellent benefit with negligible side effects from paroxetine. Notably, our
patient’s only medical comorbidity was mild hypertension, and she had excellent functionality
prior to depression onset.
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